Horie Y, Tanaka K, Okano J, Ohgi N, Kawasaki H, Yamamoto S, Kondo M, Sassa S
Second Department of Internal Medicine, Tottori University School of Medicine, Yonago.
Intern Med. 1996 Sep;35(9):717-9. doi: 10.2169/internalmedicine.35.717.
The efficacy of the H2 receptor antagonist, cimetidine, in the treatment of a patient with porphyria cutanea tarda (PCT) was evaluated. After administration of cimetidine for 2 weeks, urinary excretion of uroporphyrin (UP) and coproporphyrin (CP) was significantly decreased. Urinary porphyrin levels remained low even after the cessation of cimetidine for 1 week. Although the readministration of cimetidine did not decrease porphyrin excretion, skin lesions were markedly improved, and serum gamma-glutamyl transpeptidase (GGT), aminotransferases and serum ferritin decreased to the normal range. These results suggest that, in addition to efficacy in the treatment of acute intermittent porphyria (AIP) and erythropoietic protoporphyria (EPP), cimetidine is effective in the treatment of PCT.
评估了H2受体拮抗剂西咪替丁治疗迟发性皮肤卟啉病（PCT）患者的疗效。给予西咪替丁2周后，尿卟啉（UP）和粪卟啉（CP）的尿排泄量显著降低。即使在停用西咪替丁1周后，尿卟啉水平仍保持较低。虽然再次给予西咪替丁并未降低卟啉排泄，但皮肤病变明显改善，血清γ-谷氨酰转肽酶（GGT）、氨基转移酶和血清铁蛋白降至正常范围。这些结果表明，除了对急性间歇性卟啉病（AIP）和红细胞生成性原卟啉病（EPP）有治疗效果外，西咪替丁对PCT的治疗也有效。
